Mucosal vaccine adjuvants update.
- Author:
Joon Haeng RHEE
1
;
Shee Eun LEE
;
Soo Young KIM
Author Information
- Publication Type:Review
- Keywords: Mucosal; Vaccine; Adjuvant; Innate immunity
- MeSH: Achievement; Adaptive Immunity; Cooperative Behavior; Humans; Immunity, Innate; Immunity, Mucosal; Immunization; Mass Vaccination; Pandemics; Vaccination; Vaccines
- From:Clinical and Experimental Vaccine Research 2012;1(1):50-63
- CountryRepublic of Korea
- Language:English
- Abstract: Mucosal vaccination, capable of inducing protective immune responses both in the mucosal and systemic immune compartments, has many advantages and is regarded as a blue ocean in the vaccine industry. Mucosal vaccines can offer lower costs, better accessability, needle-free delivery, and higher capacity of mass immunizations during pandemics. However, only very limited number of mucosal vaccines was approved for human use in the market yet. Generally, induction of immune responses following mucosal immunization requires the co-administration of appropriate adjuvants that can initiate and support the effective collaboration between innate and adaptive immunity. Classically, adjuvant researches were rather empirical than keenly scientific. However, during last several years, fundamental scientific achievements in innate immunity have been translated into the development of new mucosal adjuvants. This review focuses on recent developments in the concepts of adjuvants and innate immunity, mucosal immunity with special interest of vaccine development, and basic and applied researches in mucosal adjuvant.
